BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38637772)

  • 21. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
    Huang Y; Du Z; Kan A; He M; Li H; Lai Z; Wen D; Huang L; Li Q; Xu L; Shi M
    Front Immunol; 2024; 15():1260191. PubMed ID: 38384459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma.
    Yu Q; Ungchusri E; Pillai A; Liao CY; Baker T; Fung J; DiSabato D; Zhang M; Liao C; Van Ha T; Ahmed O
    Eur Radiol; 2024 Apr; 34(4):2374-2383. PubMed ID: 37812295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
    Zhou N; Li X; Yang Y; Tan S; Zhang S; Huang Q; Gou H
    BMC Cancer; 2023 Aug; 23(1):729. PubMed ID: 37550655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable and metastatic intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
    Zhang M; Qi W; Qiu X; Yu C; Qiu W; Wang S; Qiu Z
    Radiol Oncol; 2023 Dec; 57(4):419-429. PubMed ID: 38038416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limitations of conventional doses of chemoradiation for unresectable biliary cancer.
    Crane CH; Macdonald KO; Vauthey JN; Yehuda P; Brown T; Curley S; Wong A; Delclos M; Charnsangavej C; Janjan NA
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):969-74. PubMed ID: 12095564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice.
    Wabitsch S; Tandon M; Ruf B; Zhang Q; McCallen JD; McVey JC; Ma C; Green BL; Diggs LP; Heinrich B; Greten TF
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1166-1178. PubMed ID: 34033968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
    Huang P; Huang X; Zhou Y; Yang G; Sun Q; Shi G; Chen Y
    Can J Gastroenterol Hepatol; 2022; 2022():9680933. PubMed ID: 36199981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases.
    Zhao Q; Chen Y; Du S; Yang X; Chen Y; Ji Y; Zeng Z
    Cancer Biol Ther; 2021 Mar; 22(3):175-183. PubMed ID: 33722163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
    Tachihara M; Tsujino K; Ishihara T; Hayashi H; Sato Y; Kurata T; Sugawara S; Shiraishi Y; Teraoka S; Azuma K; Daga H; Yamaguchi M; Kodaira T; Satouchi M; Shimokawa M; Yamamoto N; Nakagawa K;
    JAMA Oncol; 2023 Nov; 9(11):1505-1513. PubMed ID: 37676681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
    Yang XG; Sun YY; Li DS; Xu GH; Huang XQ
    Front Immunol; 2022; 13():940009. PubMed ID: 35874708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic artery infusion chemotherapy with systemic capecitabine and camrelizumab for treating unresectable hilar cholangiocarcinoma: An initial investigation of efficacy and safety.
    Li L; Liu S; Wang Q; Wang Y; Yu G
    J Cancer Res Ther; 2024 Apr; 20(2):578-583. PubMed ID: 38687927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
    Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
    BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
    Holster JJ; El Hassnaoui M; Franssen S; IJzermans JNM; de Jonge J; Mostert B; Polak WG; de Wilde RF; Homs MYV; Groot Koerkamp B
    Ann Surg Oncol; 2022 Sep; 29(9):5528-5538. PubMed ID: 35294656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of adoptive T-cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma.
    Kida A; Mizukoshi E; Kitahara M; Miyashita T; Goto S; Kamigaki T; Takimoto R; Asai J; Kakinoki K; Urabe T; Tomita K; Kaneko S
    Int J Cancer; 2024 Feb; 154(4):738-747. PubMed ID: 37676069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study.
    Ding X; Hua YJ; Zou X; Chen XZ; Zhang XM; Xu B; Ouyang YF; Tu ZW; Li HF; Duan CY; Zhang WJ; You R; Liu YP; Liu YL; Yang Q; Huang PY; Wang SN; Fan J; Chen MY
    EClinicalMedicine; 2023 Jul; 61():102043. PubMed ID: 37415845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of the efficacy and safety of hepatic arterial infusion chemotherapy for unresectable hepatitis B-related intrahepatic cholangiocarcinoma].
    He MR; Zheng ZK; Wu TQ; Chen MS; Zhou ZG
    Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):309-315. PubMed ID: 38432672
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of unresectable intrahepatic cholangiocarcinoma using transarterial chemoembolisation with irinotecan-eluting beads: analysis of efficacy and safety.
    Liu D; Wang J; Ma Z; Zhang N; Zhao Y; Yang X; Wen Z; Xie H
    Cardiovasc Intervent Radiol; 2022 Aug; 45(8):1092-1101. PubMed ID: 35588011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
    Lee CK; Chon HJ; Cheon J; Lee MA; Im HS; Jang JS; Kim MH; Park S; Kang B; Hong M; Kim JW; Park HS; Kang MJ; Park YN; Choi HJ
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):56-65. PubMed ID: 36328033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
    Xia L; Peng J; Lou G; Pan M; Zhou Q; Hu W; Shi H; Wang L; Gao Y; Zhu J; Zhang Y; Sun R; Zhou X; Wang Q; Wu X
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.